Rayence Vergangene Ertragsentwicklung
Vergangenheit Kriterienprüfungen 2/6
Rayence has been growing earnings at an average annual rate of 18.6%, while the Medical Equipment industry saw earnings growing at 16.7% annually. Revenues have been growing at an average rate of 5.6% per year. Rayence's return on equity is 7.1%, and it has net margins of 12.9%.
Wichtige Informationen
18.6%
Wachstumsrate der Gewinne
18.6%
EPS-Wachstumsrate
Medical Equipment Wachstum der Industrie | 22.7% |
Wachstumsrate der Einnahmen | 5.6% |
Eigenkapitalrendite | 7.1% |
Netto-Marge | 12.9% |
Letzte Ertragsaktualisierung | 30 Jun 2024 |
Jüngste Aktualisierungen vergangener Leistungen
Rayence's (KOSDAQ:228850) Profits May Not Reveal Underlying Issues
May 25Are Rayence's (KOSDAQ:228850) Statutory Earnings A Good Reflection Of Its Earnings Potential?
Feb 02Recent updates
Lacklustre Performance Is Driving Rayence Co., Ltd.'s (KOSDAQ:228850) Low P/E
Aug 12Rayence's (KOSDAQ:228850) Profits May Not Reveal Underlying Issues
May 25We Think Rayence (KOSDAQ:228850) Can Stay On Top Of Its Debt
Mar 31Rayence Co., Ltd. (KOSDAQ:228850) Is Up But Financials Look Inconsistent: Which Way Is The Stock Headed?
Mar 05Will Rayence (KOSDAQ:228850) Multiply In Value Going Forward?
Feb 17Are Rayence's (KOSDAQ:228850) Statutory Earnings A Good Reflection Of Its Earnings Potential?
Feb 02Rayence's(KOSDAQ:228850) Share Price Is Down 44% Over The Past Three Years.
Jan 18Should Rayence Co., Ltd. (KOSDAQ:228850) Be Part Of Your Dividend Portfolio?
Jan 06Income Investors Should Know That Rayence Co., Ltd. (KOSDAQ:228850) Goes Ex-Dividend Soon
Dec 25At ₩11,100, Is It Time To Put Rayence Co., Ltd. (KOSDAQ:228850) On Your Watch List?
Dec 14Rayence (KOSDAQ:228850) Seems To Use Debt Quite Sensibly
Dec 01A Look At The Intrinsic Value Of Rayence Co., Ltd. (KOSDAQ:228850)
Nov 18Aufschlüsselung der Einnahmen und Ausgaben
Wie Rayence Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.
Gewinn- und Umsatzhistorie
Datum | Einnahmen | Umsatz | Allgemeine und Verwaltungskosten | F&E-Ausgaben |
---|---|---|---|---|
30 Jun 24 | 136,322 | 17,558 | 25,413 | 13,132 |
31 Mar 24 | 141,121 | 20,963 | 25,053 | 11,452 |
31 Dec 23 | 142,986 | 19,600 | 25,421 | 10,795 |
30 Sep 23 | 145,736 | 21,118 | 26,438 | 10,805 |
30 Jun 23 | 148,751 | 19,975 | 26,285 | 10,354 |
31 Mar 23 | 148,640 | 19,932 | 26,452 | 10,103 |
31 Dec 22 | 147,161 | 22,049 | 26,035 | 9,326 |
30 Sep 22 | 146,257 | 21,570 | 24,131 | 8,660 |
30 Jun 22 | 140,174 | 18,239 | 23,656 | 8,619 |
31 Mar 22 | 139,207 | 13,087 | 21,971 | 8,411 |
31 Dec 21 | 134,568 | 14,458 | 20,253 | 8,171 |
30 Sep 21 | 129,291 | 4,328 | 19,876 | 7,593 |
30 Jun 21 | 119,423 | 552 | 19,808 | 6,517 |
31 Mar 21 | 105,745 | -25 | 19,723 | 5,552 |
31 Dec 20 | 101,524 | -1,916 | 21,337 | 4,785 |
30 Sep 20 | 106,506 | 4,466 | 21,352 | 4,189 |
30 Jun 20 | 115,408 | 9,992 | 21,622 | 3,895 |
31 Mar 20 | 125,120 | 14,398 | 22,960 | 4,186 |
31 Dec 19 | 126,175 | 14,688 | 22,261 | 3,898 |
30 Sep 19 | 120,608 | 16,018 | 22,192 | 4,277 |
30 Jun 19 | 118,165 | 15,282 | 21,281 | 4,374 |
31 Mar 19 | 116,220 | 16,006 | 20,013 | 4,147 |
31 Dec 18 | 116,389 | 15,728 | 19,336 | 4,298 |
30 Sep 18 | 114,811 | 18,597 | 17,765 | 3,760 |
30 Jun 18 | 114,491 | 18,433 | 18,110 | 3,716 |
31 Mar 18 | 110,391 | 16,389 | 18,460 | 3,720 |
31 Dec 17 | 106,518 | 14,622 | 18,689 | 3,589 |
30 Sep 17 | 108,483 | 15,477 | 20,098 | 3,872 |
30 Jun 17 | 102,915 | 14,723 | 19,237 | 3,783 |
31 Mar 17 | 100,789 | 14,598 | 18,553 | 3,936 |
31 Dec 16 | 98,457 | 14,745 | 17,316 | 4,054 |
30 Sep 16 | 93,980 | 14,072 | 15,192 | 3,791 |
30 Jun 16 | 92,467 | 14,984 | 14,842 | 3,754 |
31 Mar 16 | 88,681 | 14,513 | 14,364 | 3,650 |
31 Dec 15 | 86,609 | 14,482 | 13,697 | 3,360 |
31 Dec 14 | 77,943 | 3,217 | 13,068 | 5,499 |
31 Dec 13 | 69,183 | 3,183 | 12,702 | 5,233 |
Qualität der Erträge: A228850 has high quality earnings.
Wachsende Gewinnspanne: A228850's current net profit margins (12.9%) are lower than last year (13.4%).
Analyse von freiem Cashflow und Gewinn
Analyse des Gewinnwachstums in der Vergangenheit
Ergebnisentwicklung: A228850's earnings have grown by 18.6% per year over the past 5 years.
Beschleunigtes Wachstum: A228850's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Erträge im Vergleich zur Industrie: A228850 had negative earnings growth (-12.1%) over the past year, making it difficult to compare to the Medical Equipment industry average (4%).
Eigenkapitalrendite
Hohe Eigenkapitalrendite: A228850's Return on Equity (7.1%) is considered low.